Efficacy and safety of asciminib (ASC) in patients (pts) with chronic-phase chronic myeloid leukemia (CML-CP) after 1 tyrosine kinase inhibitor (TKI): Interim analysis (IA) of the phase 2 ASC2ESCALATE trial.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: David Jacob Andorsky, Marlise R. Luskin, Srinivas Kiran Tantravahi, Koji Sasaki, James Dugan, Celeste A. Bremer, Vivian G. Oehler, Joshua F. Zeidner, Moshe Yair Levy, Camille N. Abboud, Ehab L. Atallah, Paul B. Koller, Bonnie Kiner-Strachan, Habte Aragaw Yimer, Daisy Yang, J. Randy Sabo, Bridget Cooper, Dheeraj Gianchandani, Jorge E. Cortes, Michael J. Mauro
Institutions: Rocky Mountain Cancer Centers, Dana-Farber Cancer Institute, University of Utah, Huntsman Cancer Institute, The University of Texas MD Anderson Cancer Center, Novant Health, Virginia Oncology Associates, Fred Hutch Cancer Center, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, Baylor Scott & White Research Institute, Washington University in St. Louis, Medical College of Wisconsin, City Of Hope National Medical Center, NYU Langone’s Laura and Isaac Perlmutter Cancer Center, New York University, Trinity Mother Frances Hospitals and Clinics, Novartis (India), Memorial Sloan Kettering Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809624